{"groups":[{"description":"Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m\\^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m\\^2/day via continuous IV infusion on Days 1 to 5 Q3W (FP regimen) OR oxaliplatin 130 mg/m\\^2 IV on Day 1 Q3W + capecitabine 1000 mg/m\\^2 orally twice a day (BID) on Days 1 to 14 Q3W (CAPOX regimen).\n\nParticipants who completed up to 35 administrations of pembrolizumab (approximately 2 years) or achieved a complete response (CR) but experienced progression of disease (PD), could have initiated a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).","id":"FG000","title":"Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)"},{"description":"Participants received placebo on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m\\^2 IV on Day 1 Q3W and 5FU 800 mg/m\\^2/day via continuous IV infusion on Days 1 to 5 Q3W (FP regimen) OR oxaliplatin 130 mg/m\\^2 IV on Day 1 Q3W + capecitabine 1000 mg/m\\^2 orally BID on Days 1 to 14 Q3W (CAPOX regimen).","id":"FG001","title":"Placebo + Chemotherapy (FP or CAPOX Regimen)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"685"},{"groupId":"FG001","numSubjects":"726"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"13"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"88"},{"groupId":"FG001","numSubjects":"46"}],"type":"Sponsor Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"790"},{"groupId":"FG001","numSubjects":"789"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"785"},{"groupId":"FG001","numSubjects":"787"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"0"}],"type":"Received Pembrolizumab Second Course"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"790"},{"groupId":"FG001","numSubjects":"789"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}